Aridis Pharmaceuticals Stock Fundamentals
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Aridis Pharmaceuticals fundamentals help investors to digest information that contributes to Aridis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aridis Pink Sheet. The fundamental analysis module provides a way to measure Aridis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aridis Pharmaceuticals pink sheet.
Aridis |
Aridis Pharmaceuticals Company Shares Owned By Insiders Analysis
Aridis Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aridis Pharmaceuticals Shares Owned By Insiders | 31.53 % |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 31.53% of Aridis Pharmaceuticals are shares owned by insiders. This is 107.71% higher than that of the Biotechnology sector and 122.36% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Aridis Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aridis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aridis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aridis Pharmaceuticals competition to find correlations between indicators driving Aridis Pharmaceuticals's intrinsic value. More Info.Aridis Pharmaceuticals is rated below average in return on asset category among its peers. It is rated third in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aridis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Aridis Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aridis Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics of similar companies.Aridis Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Aridis Fundamentals
| Return On Asset | -1.08 | ||||
| Operating Margin | (9.58) % | ||||
| Current Valuation | 12.11 M | ||||
| Shares Outstanding | 36.21 M | ||||
| Shares Owned By Insiders | 31.53 % | ||||
| Shares Owned By Institutions | 11.60 % | ||||
| Number Of Shares Shorted | 2 M | ||||
| Price To Earning | (1.41) X | ||||
| Price To Book | 5.40 X | ||||
| Price To Sales | 7.33 X | ||||
| Gross Profit | (22.61 M) | ||||
| EBITDA | (29.51 M) | ||||
| Net Income | (30.37 M) | ||||
| Cash And Equivalents | 6.32 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 6.13 M | ||||
| Debt To Equity | (0.18) % | ||||
| Current Ratio | 0.41 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (29.13 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.15) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 13.24 M | ||||
| Total Asset | 14.7 M | ||||
| Retained Earnings | (195.67 M) | ||||
| Working Capital | (25.27 M) | ||||
| Current Asset | 27.39 M | ||||
| Current Liabilities | 3.06 M | ||||
| Z Score | -26.03 | ||||
| Net Asset | 14.7 M |
About Aridis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aridis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |